Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.12099PMID 23432534PMCID PMC3853528
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.

  2013cited by this paper
• OC-097 The novel gastrin/CCK2 receptor antagonist YF476 induces clinical responses and is well tolerated in patients with type I gastric neuroendocrine tumours

  2012cited by this paper
• Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose‐dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects

  2012cited by this paper
• Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A

  2012cited by this paper
• In vivo analysis of mouse gastrin gene regulation in enhanced GFP-BAC transgenic mice.

  2011cited by this paper
• Guide to Receptors and Channels (GRAC), 5th edition

  2011cited by this paper
• Dyspeptic Symptom Development After Discontinuation of a Proton Pump Inhibitor: A Double-Blind Placebo-Controlled Trial

  2010cited by this paper
• The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.

  2010cited by this paper
• Complexity of gastric acid secretion revealed by targeted gene disruption in mice.

  2010cited by this paper
• Guide to Receptors and Channels (GRAC), 4th edition

  2009cited by this paper
• Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer.

  2009cited by this paper
• Gastrin activates paracrine networks leading to induction of PAI-2 via MAZ and ASC-1.

  2009cited by this paper
• Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.

  2009cited by this paper
• Control of gastric acid secretion in somatostatin receptor 2 deficient mice: shift from endocrine/paracrine to neurocrine pathways.

  2008cited by this paper
• Gastric acid secretion in cholecystokinin-1 receptor, -2 receptor, and -1, -2 receptor gene knockout mice

  2008cited by this paper
• Genetically engineered mice: a new paradigm to study gastric physiology

  2007cited by this paper
• Attack and defence in the gastric epithelium – a delicate balance

  2007cited by this paper
• Gastrin regulates the TFF2 promoter through gastrin-responsive cis-acting elements and multiple signaling pathways.

  2007cited by this paper
• Gastrin-induced apoptosis contributes to carcinogenesis in the stomach

  2006cited by this paper
• Genetic dissection of the signaling pathways that control gastric acid secretion

  2006cited by this paper
• Increased risk of fundic gland polyps during long‐term proton pump inhibitor therapy

  2006cited by this paper
• Review article: pathogenesis and management of gastric carcinoid tumours

  2006cited by this paper
• Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.

  2005cited by this paper
• Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin.

  2005cited by this paper
• Transcriptional regulation of the human trefoil factor, TFF1, by gastrin.

  2003cited by this paper
• Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist.

  2003cited by this paper
• Gastrin agonists and antagonists.

  2002cited by this paper
• CCK2 receptors are necessary for the differentiation and proliferation of ECL cells in mouse and rat stomach

  2002cited by this paper
• Role of gastrin in the development of gastric mucosa, ECL cells and A-like cells in newborn and young rats.

  2002cited by this paper
• Validation of a liquid chromatographic-tandem mass spectrometric method for the measurement of (R)-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (YF476) in human plasma.

  2002cited by this paper
• Cellular expression of CCK-A and CCK-B/gastrin receptors in human gastric mucosa.

  2001cited by this paper
• Effect of Long-term, Continuous Versus Alternate-day Omeprazole Therapy on Serum Gastrin in Patients Treated for Reflux Esophagitis

  2001cited by this paper
• Mobilization of rat stomach ECL‐cell histamine in response to short‐ or long‐term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats

  2001cited by this paper
• Increasing concerns about chronic proton pump inhibitor use.

  2001cited by this paper
• CCK2 receptor antagonists

  2001cited by this paper
• The gastrins: their production and biological activities.

  2001cited by this paper
• Long‐lasting cholecystokinin2 receptor blockade after a single subcutaneous injection of YF476 or YM022

  2000cited by this paper
• 24-h recording of intragastric pH: technical aspects and clinical relevance.

  1999cited by this paper
• Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans

  1999cited by this paper
• Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula.

  1998cited by this paper
• (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.

  1997cited by this paper
• (3R)-N-(1-(tert-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)- 1H-1,4-benzodiazepin-3-yl)-N′-(3(methylamino)phenyl)urea (YF476): A Potent and Orally Active Gastrin/CCK-B Antagonist.

  1997cited by this paper
• YF476 is a new potent and selective gastrin/cholecystokinin‐B receptor antagonist in vitro and in vivo

  1997cited by this paper
• Evaluation of three novel cholecystokinin-B/gastrin receptor antagonists: a study of their effects on rat stomach enterochromaffin-like cell activity.

  1997cited by this paper
• A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.

  1995cited by this paper
• A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.

  1995cited by this paper
• Problems with the interpretation of gastric pH measurement

  1993cited by this paper
• The gastrin‐receptor antagonist L‐365,260 inhibits stimulated acid secretion in humans

  1993cited by this paper
• Does antral distension inhibit gastric acid secretion or stimulate bicarbonate secretion in 'healthy' subjects?

  1993cited by this paper
• Measurement of gastric bicarbonate secretion in the human stomach: different methods produce discordant results.

  1992cited by this paper
• Tolerance during 8 days of high‐dose H2‐blockade: placebo‐controlled studies of 24‐hour acidity and gastrin

  1990cited by this paper
• Carbonic anhydrase in the normal rat stomach and duodenum and after treatment with omeprazole and ranitidine.

  1989cited by this paper
• Vagal cholinergic control of gastric alkaline secretion in normal subjects and duodenal ulcer patients.

  1987cited by this paper
• Vagal stimulation of human gastric bicarbonate secretion.

  1985cited by this paper
• Gastric H+ and HCO3- secretion in response to sham feeding in humans.

  1985cited by this paper
• Gastric bicarbonate secretion in humans. Effect of pentagastrin, bethanechol, and 11,16,16-trimethyl prostaglandin E2.

  1983cited by this paper
• A demonstration of bicarbonate production by the normal human stomachin vivo

  1982cited by this paper
• Relationship between undissociated acidity of gastric juice and gastric protein secreted in response to graded doses of pentagastrin in duodenal ulcer patients.

  1977cited by this paper
• Gastric acid secretion rate and buffer content of the stomach after eating. Results in normal subjects and in patients with duodenal ulcer.

  1973cited by this paper
• Positioning of Subject and of Nasogastric Tube during a Gastric Secretion Study

  1970cited by this paper
• Undissociated acidity of human gastric juice. Measurement and relationship to protein buffers.

  1970cited by this paper
• Electrolytes in gastric juice of man. I. A statistical analysis of calcium and inorganic phosphorus before and after subcutaneous injection of large doses of histamine.

  1966cited by this paper
• Comparative potency of newer anticholinergic drugs in man, as determined by sigmoid motility technique.

  1954cited by this paper
• The buffer substances of the gastric juice, and their relation to gastric mucus

  1931cited by this paper

• Peptides for pain sensation and peptides for pain relief: Fighting fire with fire.

  2026cites this paper
• Rare epithelial gastric cancers: a review of the current treatment knowledge

  2025cites this paper
• Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice

  2024cites this paper
• The state of the art in secondary pharmacology and its impact on the safety of new medicines

  2024cites this paper
• Gastrin: a new branch of the gastropancreatic axis that can explain the effect of sleeve gastrectomy on glucose metabolism.

  2024cites this paper
• Bromophenols from Symphyocladia latiuscula (Harvey) Yamada as Novel Cholecystokinin 2 Receptor Antagonists.

  2023cites this paper
• Neuroendocrine mechanism of gastric acid secretion: Historical perspectives and recent developments in physiology and pharmacology

  2023cites this paper
• New Developments in Gastric Neuroendocrine Neoplasms

  2022cites this paper
• CCK2R antagonists: from SAR to clinical trials.

  2020cites this paper
• Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis

  2019cites this paper
• Biomarkers of the effect of gastrin on Barrett's oesophagus

  2018cites this paper
• Response: Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity

  2017cites this paper
• Netazepide, a gastrin/cholecystokinin‐2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis

  2017cites this paper
• The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment

  2016cites this paper
• Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity

  2016cites this paper
• Potential clinical indications for a CCK2 receptor antagonist.

  2016cites this paper
• Neuroendocrine Neoplasms of the Stomach

  2016cites this paper
• Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.

  2015cites this paper
• Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist

  2015cites this paper
• The regulation of gastric acid secretion – clinical perspectives

  2014cites this paper
• Review article: the investigation and management of gastric neuroendocrine tumours

  2014cites this paper
• Review article: the investigation and management of rectal neuroendocrine tumours

  2014cites this paper
• Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.

  2014cites this paper
• Gastric secretion

  2014cites this paper
• Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis

  2013cites this paper
• Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.

  2013cites this paper